Real World Effectiveness of Ustekinumab in Induction and Maintenance Therapy for Crohn´s Disease
- Conditions
- K50Crohn disease [regional enteritis]
- Registration Number
- DRKS00011811
- Lead Sponsor
- CED Service GmbH
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete
- Sex
- All
- Target Recruitment
- 901
Inclusion Criteria
CD (Crohn´s Disease)-patients aged 18-80 years at enrollment
written informed consent is given
New beginning biologica therapy
Exclusion Criteria
planned surgical intervention
malignant disease in history (approved Non-Melanoma Skin Cancer)
lack of adequate documentation possibilities
Study & Design
- Study Type
- observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Effectiveness of induction therapy (clinical remission HBI (Harvey-Bradshaw Index for assessment of disease activity) = 4) at week 16 in CD-patients treated with Ustekinumab.<br>
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What are the molecular mechanisms of ustekinumab in targeting IL-12 and IL-23 for Crohn's disease treatment?
How does ustekinumab compare to anti-TNF therapies in real-world Crohn's disease induction and maintenance outcomes?
Which biomarkers correlate with ustekinumab response in Crohn's disease patients in observational studies?
What adverse event profiles are associated with ustekinumab long-term use in Crohn's disease management?
Are there combination therapies involving ustekinumab showing improved efficacy for refractory Crohn's disease?